Change in MFSAF and MPN-SAF symptom scores from baseline in patients with MF. Percentage change in MFSAF from baseline at (A) 12 weeks and (B) 24 weeks, and in MPN-SAF from baseline at (C) 12 weeks and (D) 24 weeks in patients treated with add-on parsaclisib plus ruxolitinib. Blue bars represent daily-to-weekly parsaclisib dosing, and red bars represent all-daily parsaclisib dosing. Evaluable patients were those receiving ≥1 dose of study drug and had MFSAF or MPN-SAF baseline assessment with a nonzero value. Dotted line represents 50% decrease in MFSAF or MPN-SAF from baseline. ∗Patients had best percentage change from baseline of >100%.